Enanta Pharmaceuticals Inc (ENTA)
13.25
+0.88
(+7.11%)
USD |
NASDAQ |
Apr 29, 16:00
13.22
-0.03
(-0.23%)
After-Hours: 20:00
Enanta Pharmaceuticals Max Drawdown (5Y): 92.26% for March 31, 2024
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| March 31, 2024 | 92.26% |
| February 29, 2024 | 92.26% |
| January 31, 2024 | 92.26% |
| December 31, 2023 | 92.26% |
| November 30, 2023 | 92.26% |
| October 31, 2023 | 92.10% |
| September 30, 2023 | 89.50% |
| August 31, 2023 | 85.95% |
| July 31, 2023 | 82.85% |
| June 30, 2023 | 80.43% |
| May 31, 2023 | 80.38% |
| April 30, 2023 | 73.12% |
| March 31, 2023 | 69.83% |
| February 28, 2023 | 69.83% |
| January 31, 2023 | 69.83% |
| December 31, 2022 | 69.83% |
| November 30, 2022 | 69.83% |
| October 31, 2022 | 69.83% |
| September 30, 2022 | 69.83% |
| August 31, 2022 | 69.83% |
| July 31, 2022 | 69.83% |
| June 30, 2022 | 69.83% |
| May 31, 2022 | 69.83% |
| April 30, 2022 | 68.17% |
| March 31, 2022 | 68.17% |
| Date | Value |
|---|---|
| February 28, 2022 | 68.17% |
| January 31, 2022 | 68.17% |
| December 31, 2021 | 68.17% |
| November 30, 2021 | 68.17% |
| October 31, 2021 | 68.17% |
| September 30, 2021 | 68.17% |
| August 31, 2021 | 68.17% |
| July 31, 2021 | 68.17% |
| June 30, 2021 | 68.17% |
| May 31, 2021 | 68.17% |
| April 30, 2021 | 68.17% |
| March 31, 2021 | 68.17% |
| February 28, 2021 | 68.17% |
| January 31, 2021 | 68.17% |
| December 31, 2020 | 68.17% |
| November 30, 2020 | 68.17% |
| October 31, 2020 | 68.17% |
| September 30, 2020 | 68.17% |
| August 31, 2020 | 68.17% |
| July 31, 2020 | 68.17% |
| June 30, 2020 | 68.17% |
| May 31, 2020 | 68.17% |
| April 30, 2020 | 68.17% |
| March 31, 2020 | 68.17% |
| February 29, 2020 | 60.58% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
59.60%
Minimum
Apr 2019
92.26%
Maximum
Nov 2023
70.71%
Average
68.17%
Median
Mar 2020
Max Drawdown (5Y) Benchmarks
| Madrigal Pharmaceuticals Inc | 82.20% |
| Galectin Therapeutics Inc | 88.76% |
| Viking Therapeutics Inc | 89.26% |
| Akero Therapeutics Inc | -- |
| 89bio Inc | -- |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -36.98 |
| Beta (5Y) | 0.4723 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 53.73% |
| Historical Sharpe Ratio (5Y) | -0.5734 |
| Historical Sortino (5Y) | -0.9806 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 25.82% |